Leonhardt Ventures to Present Cardiovascular and Heart Disease Technology Showcase @ University of Minnesota
First heart pacemaker able to recruit stem cells to damaged heart tissue – THE MYOSTIM PACER – will be introduced
MINNEAPOLIS, July 5, 2013 /PRNewswire/ — Leonhardt Ventures will showcase its cardiovascular and heart disease related technologies July 8(th), 7:30pm to 9pm at The University of Minnesota, Carlson School Boardroom, Dean’s Suite, 4-300D on the 4th floor of the Carlson School of Management building, 321-19th Ave. S., Minneapolis, MN 55455. Parking is available in the 19th Avenue ramp, 300 19TH AVE S adjacent to the Carlson School.
Please RSVP to Ms. Pam Buth, at email@example.com, 612-626-9510.
Technologies to be showcased include:
MyoStim Pacers – http:/www.myostimpacers.com – world’s first heart failure pacemaker with ability to recruit reparative stem cells to damaged and weakened heart tissue.
Bioheart, Inc. – http://www.bioheartinc.com – Phase III leader in applying adult muscle stem cells to treat advanced heart failure. Only cell type known to grow new contractile muscle in the depths of scar tissue.
BioPace - biological pacemaker made entirely of living cells.
CoroStim - world’s first vibrational energy emitting pacemaker that prevents plaque formation in high risk coronary arteries.
BioLeonhardt - http://www.bioleonhardt.com – combination electrical stimulation and multi-stage cell and gene therapy method, composition and devices for treating advanced heart failure. Featuring combined utilization of MicroRNAs, nutrient time release SDF-1, hydrogel, cardiac stem cells, iPS cells and muscle progenitor stem cells. First method to utilize an implantable stem cell pump for multiple dosages of delivery of stem cells over time.
Cardiobridge - http://www.cardiobridge.com – Highest flow rate 10FR circulatory support catheter pump in clinical testing for acute decompensating heart failure and high-risk PCI. Data on about 30 clinical patients will be presented.
AortaCell - Method and device to treat aortic aneurysms non-invasively with an abdominal belt that delivers focal wireless electrical energy to weakened aortic wall that causes reparative autologous stem cells to home to that chosen treatment location and differentiate into smooth muscle.
EndoCell - Method and device for growing new endothelium lining of a damaged artery with a percutaneous needle catheter and endothelial progenitor cells.
MyoValve - Cell seeding method and device for heart valve leaflets invivo or invitro. Designed to reduce risk of calcification and valve replacement.
Valvublator - Percutaneous catheter device for de-calcifying heart valves so a patient may keep their own valve instead of getting an artificial implant.
HeartScore - Composite scoring system of genetic, blood and scan test results (some point of care) that are loaded into the SecondBeat wearable wrist watch for a baseline score. The watch has an infrared sensor that measures real time endothelial health. The baseline score goes up or down if the patient eats well, exercises well and is compliance with all doctor prescribed medicines and protocols. The composite HeartScore is clearly viewable to patients to help real time guidance of their heart and cardiovascular health.
Stem Cell Pump – world’s first implantable stem cell pump for controlled dose delivery of stem cells over time to specific target organ locations.
Stem Cell Bra and BioCell Therapies (Minnesota company) – world’s first stem cell recruiting women’s bra and a fat graft and stem cell injection method for breast tissue.
About Leonhardt Ventures: Since 1983 Leonhardt Ventures has a strong history of inventing, developing, backing and bringing to market leadership products for treating heart and cardiovascular disease. Over 200,000 patients have been treated to date with Leonhardt inventions. Leonhardt Venture’s started the Cal-X Stars Innovation and Business Accelerator in 2012 to guide forward cardiovascular and social good impact innovations over a 5 year period in preparation for a listing on the future California Stock Exchange (SEC registration application in process). June 11th, 2013 Leonhardt Ventures announced that it has chosen Core Manufacturing in Valencia, California for manufacturing and product development services for its lineup of active implantable devices – http://www.cnbc.com/id/100806225
Contact: Howard Leonhardt, Leonhardt Ventures, 1531 6(th) Street, Unit 401, Santa Monica, California, 90401, 310 310 2534, Email
This PR distribution was issued via PR Syndication.
SOURCE Leonhardt Ventures